What Actually Drives Antibiotic Resistance on British Farms

Whether farming method changes how much antimicrobial resistance ends up in the food chain is one of those questions that sounds like it should have a simple answer, organic and free range surely carry less risk than intensive systems built around routine antibiotic use. Two studies published in 2026 complicate that assumption in different ways. One looked at what is actually sitting on food by the time it reaches a shop shelf. The other spent a decade inside a single working dairy farm to see what really drives resistance once you look past the farming label altogether.

At the Shop, Production Method Barely Registers

Researchers at the Quadram Institute, led by Sam Mellor alongside Samuel Bloomfield, Alison Mather and colleagues, examined 223 retail food samples collected in Norfolk between 2018 and 2024, covering pork, beef, lamb, chicken, salmon and leafy greens across three production categories, extensive, wild caught and intensive. Using shotgun metagenomics, a technique that sequences all the microbial DNA present in a sample rather than testing for specific bacteria, the team mapped both the microorganisms and the antimicrobial resistance genes found on each product, work published in Microbial Genomics in April 2026.

The dominant organisms found were spoilage bacteria, Pseudomonas, Lactococcus and Psychrobacter among them, of the kind acquired during processing and storage rather than on the farm itself, and tetracycline and beta lactam resistance genes made up the bulk of the resistance profiles across every food type tested, regardless of how it had been produced. On most measures, production method made no statistically significant difference to antimicrobial resistance gene burden. Chicken and salmon showed some difference in microbial diversity between intensive and extensive or wild caught systems, but the effect size was small. As Mellor put it, “food processing, post farm production, shapes the composition of microbiome on retail food, while the influence of on-farm practices is limited.” The paper’s own conclusion was blunter still, differently produced foods may not present an increased risk of antimicrobial resistance across the commodities the study covered.

Inside One Farm, the Real Drivers Come Into Focus

The second study took the opposite approach, going deep rather than wide. A team led by researchers at the University of Nottingham, including Jon Hobman and Dov Stekel, spent ten years studying antimicrobial resistance in waste from a single intensive dairy farm, a 220 cow Holstein Friesian herd in the East Midlands, sampling in two main windows, late 2012 to early 2014 and 2017 to early 2018. The work, published in Frontiers in Veterinary Science in August 2026, combined whole genome sequencing, genetic fingerprinting of E. coli isolates and mathematical modelling to track how resistance actually changed over time.

Resistance levels were stable over short periods but shifted over the long term in step with real changes in antibiotic use on the farm, most clearly when the farm stopped using cephalosporin antibiotics in 2015 and 2016, after which resistance to that drug class fell. The researchers found that resistant strains were spreading mainly through clonal expansion, existing resistant bacteria multiplying and persisting, rather than through resistance genes jumping between different bacteria. A significant driver alongside antibiotics themselves was co-selection by copper, zinc and tetracycline, substances that persist in the farm environment and keep already resistant bacteria at an advantage even when no antibiotic is directly involved. The team also compared resistance patterns in their farm’s E. coli against clinical E. coli from a nearby hospital, and concluded the differences looked more like each sector’s own antibiotic use shaping its own resistance patterns separately, rather than resistant bacteria passing directly between livestock and people. From the decade of data the researchers set out practical priorities for reducing resistance on farms, among them cutting antibiotic use through better infection control, avoiding antibiotics that are also critical in human medicine, managing copper and zinc contaminated waste and storing slurry separately before it goes on fields.

Two Different Answers to a Similar Question

Put side by side, the two studies are not contradicting each other so much as answering different parts of the same question. Whether a product on a supermarket shelf was raised intensively or extensively does not, on this evidence, meaningfully change the antimicrobial resistance risk it carries by the time it reaches a shopper, because what happens during processing after the animal leaves the farm matters more than how it was raised. But inside a working farm itself, resistance is shaped by specific, changeable practices, which antibiotics are used and for how long, and what else, like copper and zinc, is being used alongside them, rather than by whether the farm counts as intensive in the first place. Neither finding supports the simplest version of the usual argument, that buying organic protects a shopper from resistant bacteria, or that intensive farming is straightforwardly the source of the problem. What both studies point to instead is that the details of practice, not the label on the system, are where the actual risk sits.

Sources: Microbial Genomics (Mellor et al, 2026); Quadram Institute; Frontiers in Veterinary Science (Stekel, Hobman et al, 2026).

Author

Leave A Comment

Graham Combe

Strategic Consultant,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Graham Combe is an experienced strategic consultant, relationship builder, and entrepreneur in the global life sciences sector. He holds a BSc (Hons) in Chemistry from University College London (UCL) and spent over a decade with Nature, where he pioneered key initiatives such as Nature’s BioPharma Dealmakers and Nature’s SciCafe.

In May 2011, he founded Biosell UK, a consulting and event management firm that collaborates with global life science publishers, event organizations, and marketing partners. Beyond BioSell, Combe is the founder or co-founder of several prominent networking and thought-leadership platforms, including #BiotechBuddies, #coffeebuddies, the #AgileLeaders Forum, and the Creative Disruption Forum—the latter three events co-hosted with his business partner, Professor Tony Sedgwick.

Specializing in the early-to-mid stages of drug development (from pre-clinical research through Phase 3 and clinical proof-of-concept), Graham focuses on facilitating forums to promote peer-to-peer discussion, strategic growth, investment and meaningful connections between biotech innovators, investors, and industry service providers.

Apply for a complimentary Conference Day VIP Pass

Apply for a complimentary Conference Day VIP Pass

Complimentary Conference Day VIP Passes are reserved for senior leaders and decision-makers with influence over purchasing, commissioning, investment or technology advancements and adoption across UK life sciences.

A Conference Day VIP Pass includes:

  • Complimentary access-all-areas to the Launch Day Conference
  • Access to the dedicated VIP green room alongside Conference speakers
  • Access to all general keynote, panel and programme sessions
  • Curated networking opportunities
  • Opportunities to meet conference speakers and other approved VIP attendees

The VIP Pass applies to the Launch Day Conference only. It does not include admission to the Life Sciences Week Gala Dinner or other separately ticketed events.

Applications are reviewed individually and submitting this form does not guarantee a complimentary pass. To maintain a balanced, high-quality audience, we may limit the number of VIP Passes issued to any one organisation.

    First Name *

    Last Name *

    Work Email Address *

    Telephone Number *

    Job Title *

    Organisation *

    LinkedIn

    Organisation Information

    Which best describes your organisation? *


    If other, please specify

    Which best describes your level of seniority? *

    If other, please specify

    Which areas are you responsible for or directly involved in? *

    If other, please specify

    What best describes your role in purchasing, investment, commissioning or adoption decisions? *

    Attendance Information

    Briefly, what is the number one thing you are hoping to get out of attending Life Sciences Week 2026? *

    Final Confirmation

    Is your role primarily focused on selling products or services, consultancy, account management or business development? *

    Please Confirm *

    I understand that VIP applications are subject to review and approval.
    I understand that the complimentary VIP Pass covers the Life Sciences Week Launch Day Conference only and does not include the Gala Dinner Awards or other separately ticketed events.
    The information supplied in this application is accurate.

    Shabna Raja

    Advisory Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Shabna Raja is a senior leader in enterprise transformation within Life Sciences, with over 20 years’ experience spanning pharma, consumer health and large-scale digital programmes.

    She specialises in bridging strategy and execution – helping organisations translate AI, data and digital innovation into tangible business outcomes. Her work focuses on complex transformation
    initiatives across commercial, data and operating model domains within regulated environments.

    Shabna spent seven years at GSK, where she played a key role in transformation programmes, including as part of the Consumer Health joint venture with Pfizer — one of the most significant integrations in the sector. This experience provided her with deep expertise in  organisational change, integration and operating model evolution at global scale.

    More recently, she has spent over three years working closely with Haleon through a strategic
    services partnership, leading enterprise client engagement and managing a multi-million-pound account while supporting transformation across a newly independent global organisation.

    Her experience spans the end-to-end life sciences value chain, including R&D, commercial, supply chain and patient engagement, giving her a holistic perspective on how technology and transformation can unlock value across the industry.

    Amjad Khan

    Executive Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Amjad Khan is a UK-based entrepreneur, AI strategist, and senior technology leader with over 15 years of experience at Pfizer, where he held multiple leadership roles across digital strategy and transformation. As Global Digital Client Partner, he was responsible for digital strategy and execution across Global Business Units covering Vaccines, Hospital, and Medical Affairs. Most notably, he led the commercial launch for the Covid franchise transforming and accelerating the model for how new medicines are brought to market.

    Following his tenure at Pfizer, Amjad channelled his expertise into building at the frontier of AI. His work spans AI leadership, stakeholder engagement, and agile delivery helping organisations adopt and scale emerging  technologies to drive meaningful outcomes.

    Dr. Richard Fallon | Business Consultant | WM Life Sciences

    Dr. Richard Fallon

    Co Founder, Life Sciences Week 
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Dr Richard Fallon is an entrepreneur and ecosystem builder who connects industry leaders, investors and public-sector stakeholders to accelerate collaboration and commercial growth.

    As the Founder of the Technology Supply Chain and co-founder of the Innovation Awards, he has spent more than two decades convening influential networks that help emerging businesses find capital, strategic partners and new routes to market.

    Richard’s work spans leadership and consultancy across major organisations, alongside building membership and partnership platforms that bring universities, industry and investors into the same room – and turn conversations into practical outcomes.

    With his focus on life sciences, Richard supports organisations and people driving breakthroughs in healthcare, biotechnology, medical technology and advanced research. He is passionate about creating the conditions for transformative ideas to move from concept to real-world impact – by connecting innovators with the funding, expertise and opportunities they need to scale.

    Through Life Sciences Week, Richard is championing the UK’s world-class life sciences community and helping position it at the forefront of innovation, investment and patient outcomes.

    Amy Deakin | Chief of Staff | WM Life Sciences

    Amy Deakin

    Event Managing Director,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Amy Deakin is a Birmingham-based leader specialising in building partnerships and fostering innovation in the life sciences sector. With a degree in Sport and Exercise Science, Amy brings a grounded understanding of human health and performance to her work and a strong interest in the developments shaping healthcare today.

    Amy is Managing Director of Life Sciences Week, part of the One Thousand Trades Group, and also serves as Director of One Thousand Trades Events. In these roles, she convenes researchers, clinicians and industry leaders to strengthen collaboration, unlock new partnerships and help accelerate real-world innovation across the life sciences ecosystem.

    Her career spans both commercial and third-sector environments. She began in automotive design, delivering projects for Volkswagen, McLaren, Bentley and Jaguar Land Rover, before moving into the third sector with Acorns Children’s Hospice. She later joined Western Union, working as a Partnerships Manager for international payments

    An avid netballer, Amy is a committed advocate for health and wellbeing – bringing energy, clarity and connection to everything she builds, and actively involved as a participant in health related research studies.

      Award Category Voting

      Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

      Day you've not voted in, will be denoted with an ❌

      If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

      Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

      Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

      No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

      Awarding an individual or organisation for exceptional long-term impact on the industry.

      No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

      Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

      No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

      Your Details